Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275457 | 0.86 | KDM4C (0.41) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL22275507 | 0.86 | KDM4C (0.41) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL24006643 | 0.85 | KDM4C (0.40) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL24015128 | 0.84 | KDM4C (0.42) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25108309 | 0.83 | KDM4C (0.39) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25108415 | 0.83 | KDM4C (0.39) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL1220698 | 0.81 | PPARA (0.43) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL2251531 | 0.81 | KDM4C (0.41) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25107990 | 0.80 | KDM4C (0.42) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL11971241 | 0.80 | NPC1 (0.43) | NPC1RAB9AMEN1KMT2ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115916196-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916754-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4146205-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021226269-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226208-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | KDM4C 959/4885NPC1 237/4885RAB9A 3265/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | KDM4C 976/4885NPC1 273/4885RAB9A 3355/4885 |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | KDM4C 976/4885NPC1 273/4885RAB9A 3355/4885 |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | KDM4C 976/4885NPC1 273/4885RAB9A 3355/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | KDM4C 976/4885NPC1 273/4885RAB9A 3355/4885 |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | KDM4C 1204/4885NPC1 314/4885RAB9A 3178/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | KDM4C 1272/4885NPC1 319/4885RAB9A 3155/4885 |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | KDM4C 1272/4885NPC1 319/4885RAB9A 3155/4885 |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | KDM4C 1204/4885NPC1 314/4885RAB9A 3178/4885 |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | KDM4C 959/4885NPC1 237/4885RAB9A 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.